American Vanguard (AVD) 10-Q 8 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 01, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		29,865,756

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Net sales	$ 104,108	$ 70,673
Cost of sales	63,057	40,589
Gross profit	41,051	30,084
Operating expenses	33,700	24,951
Operating income	7,351	5,133
Interest expense, net	837	298
Income before provision for income taxes and loss on equity method investments	6,514	4,835
Income tax expense	1,692	1,380
Income before loss on equity method investments	4,822	3,455
Loss from equity method investments	217	42
Net income	4,605	3,413
Loss attributable to non-controlling interest	50	39
Net income attributable to American Vanguard	$ 4,655	$ 3,452
Earnings per common share—basic	$ 0.16	$ 0.12
Earnings per common share—assuming dilution	$ 0.16	$ 0.12
Weighted average shares outstanding—basic	29,282	28,947
Weighted average shares outstanding—assuming dilution	29,972	29,654

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 4,605	$ 3,413
Comprehensive income:
Foreign currency translation adjustment	672	757
Comprehensive income	5,277	4,170
Loss attributable to non-controlling interest	50	39
Comprehensive income attributable to American Vanguard	$ 5,327	$ 4,209

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 13,018	$ 11,337
Receivables:
Trade, net of allowance for doubtful accounts of $298 and $46, respectively	111,638	102,534
Other	10,765	7,071
Total receivables, net	122,403	109,605
Inventories	143,231	123,124
Prepaid expenses	11,390	10,817
Total current assets	290,042	254,883
Property, plant and equipment, net	48,579	49,321
Intangible assets, net of applicable amortization	178,283	180,950
Goodwill	22,983	22,184
Other assets	26,906	28,254
Total assets	566,793	535,592
Current liabilities:
Current installments of other liabilities	5,475	5,395
Accounts payable	63,820	53,748
Deferred revenue	11,858	14,574
Accrued program costs	43,688	39,054
Accrued expenses and other payables	9,011	12,061
Income taxes payable	880	1,370
Total current liabilities	134,732	126,202
Long-term debt, net	90,325	77,486
Other liabilities, excluding current installments	10,328	10,306
Deferred income tax liabilities	17,250	16,284
Total liabilities	252,635	230,278
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 32,668,923 shares at March 31, 2018 and 32,241,866 shares at December 31, 2017	3,267	3,225
Additional paid-in capital	77,735	75,658
Accumulated other comprehensive loss	(3,835)	(4,507)
Retained earnings	245,056	238,953
Less treasury stock at cost, 2,450,634 shares at March 31, 2018 and December 31, 2017	(8,269)	(8,269)
American Vanguard Corporation stockholders’ equity	313,954	305,060
Non-controlling interest	204	254
Total stockholders’ equity	314,158	305,314
Total liabilities and stockholders' equity	$ 566,793	$ 535,592

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 298	$ 46
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	32,668,923	32,241,866
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance at Dec. 31, 2017	$ 305,314	$ 3,225	$ 75,658	$ (4,507)	$ 238,953	$ (8,269)	$ 305,060	$ 254
Balance (in shares) at Dec. 31, 2017	32,241,866	32,241,866				2,450,634
Adjustment to recognize new revenue recognition standard, net of tax	$ 2,214				2,214		2,214
Adjustment to recognize new standard on taxes on foreign asset transfers	(180)				(180)		(180)
Stocks issued under ESPP	299	$ 1	298				299
Stocks issued under ESPP (in shares)		17,078
Cash dividends on common stock ($0.020 per share)	(586)				(586)		(586)
Foreign currency translation adjustment, net	672			672			672
Stock based compensation	1,309		1,309				1,309
Stock options exercised; grants, termination and vesting of restricted stock units (net of shares in lieu of taxes)	511	$ 41	470				511
Stock options exercised; grants, termination, and vesting of restricted stock units (net of shares in lieu of taxes), Shares		409,979
Net income	4,605				4,655		4,655	(50)
Balance at Mar. 31, 2018	$ 314,158	$ 3,267	$ 77,735	$ (3,835)	$ 245,056	$ (8,269)	$ 313,954	$ 204
Balance (in shares) at Mar. 31, 2018	32,668,923	32,668,923				2,450,634

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)	3 Months Ended
	Mar. 31, 2018$ / shares
Statement Of Stockholders Equity [Abstract]
Cash dividends on common stock, per share	$ 0.020

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net income	$ 4,605	$ 3,413
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization of fixed and intangible assets	4,983	3,939
Amortization of other long term assets and debt issuance costs	1,163	1,423
Amortization of discounted liabilities	102	6
Stock-based compensation	1,309	1,080
Increase in deferred income taxes		8
Operating loss from equity method investment	217	42
Changes in assets and liabilities associated with operations:
(Increase) decrease in net receivables	(9,303)	11,422
Increase in inventories	(19,558)	(1,366)
Increase in prepaid expenses and other assets	(562)	(1,126)
(Increase) decrease in income tax receivable/payable, net	(497)	793
Increase (decrease) in accounts payable	9,613	(3,025)
Decrease in deferred revenue	(2,740)	(394)
Increase in accrued program costs	4,634	6,612
Decrease in other payables and accrued expenses	(3,201)	(5,657)
Net cash (used in) provided by operating activities	(9,235)	17,170
Cash flows from investing activities:
Capital expenditures	(1,553)	(3,080)
Acquisitions of businesses and intangible assets	(815)	(300)
Net cash used in investing activities	(2,368)	(3,380)
Cash flows from financing activities:
Payments under line of credit agreement	(23,000)	(27,000)
Borrowings under line of credit agreement	35,800	16,000
Net payments from the issuance of common stock (sale of stock under ESPP, exercise of stock options, and shares purchased for tax withholdings)	810	303
Payment of cash dividends	(438)	(289)
Net cash provided by (used in) financing activities	13,172	(10,986)
Net increase in cash and cash equivalents	1,569	2,804
Cash and cash equivalents at beginning of period	11,337	7,869
Effect of exchange rate changes on cash and cash equivalents	112	119
Cash and cash equivalents at end of period	$ 13,018	$ 10,792

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Revenue Recognition	2. Revenue Recognition—The Company recognizes revenue from the sale of its products, which include insecticides, herbicides, soil fumigants, and fungicides. The Company sells its products to customers, which include distributors and retailers. In addition, the Company recognizes royalty income from the sale of intellectual property. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended March 31, 2018 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 41,293 $ 41,317 Herbicides/soil fumigants/fungicides 32,185 32,185 Other, including plant growth regulators and distribution 17,840 17,840 91,318 91,342 Non-crop, including distribution 12,790 12,790 Total net sales: $ 104,108 $ 104,132 Net sales: US $ 69,815 $ 69,839 International 34,293 34,293 Total net sales: $ 104,108 $ 104,132 Timing of revenue recognition: Goods transferred at a point in time $ 103,705 $ 104,132 Goods and services transferred over time 403 — Total net sales: $ 104,108 $ 104,132 In May 2014, Financial Accounting Standards Board, (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers The Company adopted ASC 606 using the modified retrospective method, therefore, the comparative information has not been adjusted and continues to be reported under ASC 605. As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less (ii) allowing entities the option to treat shipping and handling activities that occur after control of the good transfers to the customer as fulfillment activities. For all of the Company’s sales and distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs at shipment for product sales, but also occurs over time for certain products that are deemed to have no alternative use accompanied by an enforceable right to payment for performance completed to date. For revenue recognized over time, the Company uses an output measure, units produced, to measure progress. From time to time, the Company may offer a program to eligible customers, in good standing, that provides extended payment terms on a portion of the sales on selected products. The Company analyzes these extended payment programs in connection with its revenue recognition policy to ensure all revenue recognition criteria are satisfied at the time of sale. Performance Obligations — A performance obligation is a promise in a contract or sales order to transfer a distinct good or service to the customer, and is the unit of account in ASC 606. A transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Certain of the Company’s sales orders have multiple performance obligations, as the promise to transfer individual goods or services is separately identifiable from other promises in the sales orders. For sales orders with multiple performance obligations, the Company allocates the sales order’s transaction price to each performance obligation based on its relative stand-alone selling price. The stand-alone selling prices are determined based on the prices at which the Company separately sells these products. The Company’s performance obligations are satisfied at a point in time or over time as work progresses. At March 31, 2018, the Company had $44,079 of remaining performance obligations, which is comprised of deferred revenue and services not yet delivered. The Company expects to recognize approximately all of its remaining performance obligations as revenue in fiscal 2018. Contract Balances — The timing of revenue recognition, billings and cash collections results in deferred revenue in the consolidated balance sheet. The Company sometimes receives payments from its customers in advance of goods and services being provided in return for early cash incentive programs, resulting in deferred revenues. These liabilities are reported on the consolidated balance sheet at the end of each reporting period. The following table provides information about receivables and contract liabilities from contracts with customers: March 31, 2018 December 31, 2017 Total receivables, net $ 122,403 $ 109,605 Contract assets 3,000 — Deferred revenue 11,858 14,574 Revenue recognized for the three months ended March 31, 2018, that was included in the deferred revenue balance at the beginning of 2018 was $12,740. Adjustments to Previously Reported Financial Statements from the Adoption of Accounting Pronouncements The following table presents the effect of the adoption of ASU 2014-09 on our condensed consolidated balance sheet (unaudited) as of December 31, 2017, (in thousands): As of December 31, 2017 As previously reported Adjustment due to adoption of ASC 606 As adjusted Total assets $ 535,592 $ 3,000 $ 538,592 Deferred income tax liabilities, net 16,284 786 17,070 Retained earnings 238,953 2,214 241,167 In accordance with ASC 606, the disclosure of the impact of adoption to our consolidated statements of operations was $24 reduction in net sales. This revenue will move from being recognized at point in time to be recognized over time. As such, the net sales will be reported as sales in a later quarter. In accordance with ASC 606, the disclosure of the impact of adoption to our condensed consolidated balance sheet was as follows: As of March 31, 2018 As reported Balances without adoption of ASC 606 Impact Assets: Contract assets $ 3,000 $ — $ 3,000 Current liabilities: Deferred revenue 11,858 11,834 24 Deferred income tax liabilities 786 — 786 Stockholders' equity: Retained earnings 245,056 242,842 2,214

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2018
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	3. Property, plant and equipment at March 31, 2018 and December 31, 2017 consists of the following: March 31, 2018 December 31, 2017 Land $ 2,458 $ 2,458 Buildings and improvements 16,732 16,678 Machinery and equipment 108,250 107,722 Office furniture, fixtures and equipment 5,179 4,713 Automotive equipment 1,010 735 Construction in progress 2,027 1,917 Total 135,656 134,223 Less accumulated depreciation (87,077 ) (84,902 ) Property, plant and equipment, net $ 48,579 $ 49,321 The Company recognized depreciation expense related to property and equipment of $2,303 and $1,950 for the three months ended March 31, 2018 and 2017, respectively. During the three months ended March 31, 2018 and 2017, the Company eliminated from assets and accumulated depreciation $128 and $1,175, respectively, of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral with its lender banks.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventories	4. Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: March 31, 2018 December 31, 2017 Finished products $ 125,498 $ 107,595 Raw materials 17,733 15,529 $ 143,231 $ 123,124 As of March 31, 2018, we believe our inventories are valued at lower of cost or net realizable value. In July 2015, FASB issued ASU 2015-11, Inventory (ASC 330). ASC 330 previously required an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this new standard effective January 1, 2017. There was no impact on this adoption.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment Reporting	5. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended March 31 2018 2017 Net sales: Crop: Insecticides $ 41,293 $ 37,942 Herbicides/soil fumigants/fungicides 32,185 20,021 Other, including plant growth regulators and distribution 17,840 3,392 91,318 61,355 Non-crop, including distribution 12,790 9,318 Total net sales: $ 104,108 $ 70,673 Net sales: US $ 69,815 $ 52,244 International 34,293 18,429 Total net sales: $ 104,108 $ 70,673

Accrued Program Costs

Accrued Program Costs	3 Months Ended
	Mar. 31, 2018
Payables And Accruals [Abstract]
Accrued Program Costs	6. Accrued Program Costs The Company offers various discounts to customers based on the volume purchased within a defined time period, other pricing adjustments, some grower volume incentives or other key performance indicator driven payments made to distributors, retailers or growers, at the end of a growing season. The Company describes these payments as “Programs.” Programs are a critical part of doing business in both the US agricultural and non-crop chemicals market places. These discount Programs represent variable consideration. In accordance with ASC 606, revenue from sales is recorded at the net sales price, which is the transaction price, and includes estimates of variable consideration. Variable consideration includes amounts expected to be paid to its customers estimated using the expected value method. Each quarter management compares individual sale transactions with programs to determine what, if any, estimated program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management, along with executive and financial management, review the accumulated program balance and, for volume driven payments, make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in agreed upon terms and conditions attached to each Program. Following this assessment, management will make adjustments to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at, or close to, the end of the crop season, at which time customer performance can be more fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year. No significant changes in estimates were made during the three months ended March 31, 2018 and 2017, respectively.

Cash Dividend

Cash Dividend	3 Months Ended
	Mar. 31, 2018
Cash Dividends [Abstract]
Cash Dividend	7. The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid March 8, 2018 March 30, 2018 April 13, 2018 $ 0.020 $ 586 December 12, 2017 December 27, 2017 January 10, 2018 $ 0.015 $ 438

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share	8. ASC 260 Earnings Per Share (“EPS”) The components of basic and diluted earnings per share were as follows: Three Months Ended March 31, 2018 2017 Numerator: Net income attributable to AVD $ 4,655 $ 3,452 Denominator: Weighted averages shares outstanding-basic 29,282 28,947 Dilutive effect of stock options and grants 690 707 29,972 29,654 For the three months ended March 31, 2018 and 2017, no stock options were excluded from the computation of diluted earnings per share.

Indebtedness

Indebtedness	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Indebtedness	9. The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at March 31, 2018 and December 31, 2017. The Company has no short term debt as of March 31, 2018 and December 31, 2017. The debt is summarized in the following table: Long-term indebtedness ($000's) March 31, 2018 December 31, 2017 Revolving line of credit $ 91,225 $ 78,425 Deferred loan fees (900 ) (939 ) Total indebtedness $ 90,325 $ 77,486 As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West as agent, swing line lender and Letter of Credit issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA as defined in the Credit Agreement, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. At March 31, 2018, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $124,936, according to the terms of the Credit Agreement. This compares to an available borrowing capacity of $119,994 as of March 31, 2017. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve month period and proforma basis arising from acquisitions, which have improved, (2) net borrowings, which have increased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

Reclassification

Reclassification	3 Months Ended
	Mar. 31, 2018
Text Block [Abstract]
Reclassification	10. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the March 31, 2018 presentation.

Comprehensive income

Comprehensive income	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Comprehensive income	11. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three month period ended March 31, 2018, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	12. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment, The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months ended March 31, 2018 and 2017. Stock-Based Compensation for the Three months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) March 31, 2018 Restricted Stock $ 666 $ 7,956 2.0 Unrestricted Stock $ 96 $ 64 0.2 Performance Based Restricted Stock 547 3,562 2.4 Total $ 1,309 $ 11,582 March 31, 2017 Incentive Stock Options $ 84 $ 293 0.8 Restricted Stock 581 5,388 2.3 Unrestricted Stock 75 50 0.2 Performance Based Restricted Stock 300 2,385 2.5 Performance Based Options 40 128 0.8 Total $ 1,080 $ 8,244 Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Balance outstanding, December 31, 2017 472,783 $ 9.38 Options exercised (40,923 ) 11.49 Options forfeited — — Balance outstanding, March 31, 2018 431,860 $ 9.19 All outstanding awards were vested as of March 31, 2018 and the intrinsic value was $4,757. Information relating to stock options at March 31, 2018, summarized by exercise price is as follows: Outstanding Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Incentive Stock Option Plan: $7.50 249,050 32 $ 7.5 $11.32—$14.49 182,810 77 $ 11.49 431,860 51 $ 9.19 Common stock grants — Three Months Ended March 31, 2018 Three Months Ended March 31, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 391,753 $ 15.63 324,756 $ 14.75 Granted 254,972 19.97 251,475 16.10 Vested (8,800 ) 12.07 (10,100 ) 12.95 Forfeited (5,265 ) 16.51 (6,544 ) 15.26 Nonvested shares at March 31 st 632,660 $ 17.42 559,587 $ 15.38 Common stock grants — During the three months ended March 31, 2018, the Company issued a total of 254,972 shares of restricted common stock to employees. The shares will cliff vest after three years of service. The shares granted in 2018 were average fair valued at $19.97 per share. The fair value was determined by using the publicly traded share price at market close as of the date of grant. The Company will recognize as expense the value of restricted shares over the required service period. During the three months ended March 31, 2017, the Company issued a total of 251,475 shares of restricted common stock to employees. The shares will cliff vest after three years of service. The shares granted in 2017 were average fair valued at $16.10 per share. The fair value was determined by using the publicly traded share price at market close as of the date the grant was approved. The Company will recognize as expense the value of restricted shares over the required service period. As of March 31, 2018 and 2017, the Company had approximately $7,956 and $5,388, respectively, of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.0 and 1.4 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Shares — Three Months Ended March 31, 2018 Three Months Ended March 31, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 186,057 $ 14.93 119,022 $ 14.18 Granted 122,446 18.14 121,194 15.40 Vested (14,625 ) 11.09 — — Forfeited (1,765 ) 15.40 — — Nonvested shares at March 31 st 292,113 $ 16.46 240,216 $ 14.80 Performance Based Shares — During the three months ended March 31, 2018, the Company issued a total of 122,446 performance based shares to employees. The shares granted during the first quarter of 2018 have an average fair value of $18.14. The fair value was determined by using the publicly traded share price at market close as of the date of grant. The Company will recognize as expense the value of the performance based shares over the required service period from grant date. During the three months ended March 31, 2017, the Company issued a total of 121,194 performance based shares to employees. The shares granted during the first quarter of 2018 have an average fair value of $15.40. The fair value was determined by using the publicly traded share price at market close as of the date of grant. The Company will recognize as expense the value of the performance based shares over the required service period from grant date. As of March 31, 2018, performance based shares related to earnings before income tax (“EBIT”) and net sales have an average fair value of $19.95 per share. The fair value was determined by using the publicly traded share price at market close as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $16.49 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. As of March 31, 2018 and 2017, the Company had approximately $3,562 and $2,385, respectively, of unamortized stock-based compensation expense related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.4 and 1.3 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the three months ended March 31, 2018 and 2017, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Balance outstanding, December 31, 2017 and March 31, 2018 81,666 $ 11.49 All outstanding awards were vested as of March 31, 2018 and the intrinsic value was $711. Information relating to stock options at March 31, 2018 summarized by exercise price is as follows: Outstanding Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Performance Incentive Stock Option Plan: 81,666 81 $ 11.49 In March 2016, FASB issued ASU 2016-09, Compensation—Stock Compensation (ASC 718)

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	13. Legal Proceedings— During the reporting period, there have been no material developments in legal proceedings that were reported in the Company’s Form 10-K for the year ended December 31, 2017, except as described below. Abad Castillo and Marquinez Chavez. Walker v. AMVAC EPA FIFRA/RCRA Matter.

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Recently Issued Accounting Guidance	14. Recently Issued Accounting Guidance— In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-02, Income Statement-Reporting Comprehensive Income (ASC 220) In January 2018, the FASB released guidance on the accounting for tax on the global intangible low-taxed income (“GILTI”) provisions of the Tax Cuts and Jobs Act (the “Act”). The GILTI provisions imposed a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has considered options regarding the accounting treatment for any potential GILTI inclusions and has elected to treat such inclusions as period costs. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (ASC 350). In October 2016, FASB issued ASU 2016-16, Income Taxes (ASC 740) In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (ASC 230) In February 2016, FASB issued ASU 2016-02, Leases The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available. We are currently evaluating our operating lease arrangements to determine the impact of this amendment on the consolidated financial statements, but we expect this adoption will result in a material increase in the assets and liabilities on our consolidated balance sheet. We have not determined if the adoption of this standard will materially impact our operating results. The evaluation will include an extensive review of our leases, which are primarily related to our manufacturing sites, regional sales offices, lease vehicles, and office equipment. The ultimate impact will depend on the Company’s lease portfolio at the time the new standard is adopted. The Company will adopt ASU 2016-02 for the year beginning on January 1, 2019. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." The amendment requires (i) equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, (ii) public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes and (iii) separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (i.e., securities or loans and receivables). This amendment eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. This amendment is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the provisions of ASU 2016-01 on January 1, 2018 and has elected to measure its cost method investment without a readily determinable fair value at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no observable price changes in the quarter ended March 31, 2018. If there are any observable price changes related to this investment or a similar investment of the same issuer in fiscal years beginning after December 15, 2017, the Company would be required to assess the fair value impact, if any, on each class of stock, and write the individual security interest up or down to its estimated fair value, which could have a significant effect on the Company's financial position and results of operations. In September 2015, FASB issued ASU 2015-16, Business Combination (Topic 805).

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	15. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt payable to bank.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Accumulated Other Comprehensive Income ("AOCI")	16. Accumulated Other Comprehensive Income (“AOCI”) — Total Balance, December 31, 2016 $ (4,851 ) FX translation 344 Balance, December 31, 2017 (4,507 ) FX translation 672 Balance, March 31, 2018 $ (3,835 )

Equity Method Investments

Equity Method Investments	3 Months Ended
	Mar. 31, 2018
Equity Method Investments And Joint Ventures [Abstract]
Equity Method Investments	17. Equity Method Investments — On June 27, 2017, both Amvac Netherlands BV and Huifeng Agrochemical Company, Ltd (“Huifeng”) made individual capital contributions of $950 to the Huifeng Amvac Innovation Co. Ltd (“Hong Kong Joint Venture”). As of March 31, 2018, the Company’s ownership position in the Hong Kong Joint Venture was 50%. The Company utilizes the equity method of accounting with respect to this investment. On July 7, 2017, the Hong Kong Joint Venture purchased the shares of Profeng Australia, Pty Ltd.(“Profeng”), for a total consideration of $1,900. The purchase consists of Profeng Australia, Pty Ltd Trustee and Profeng Australia Unit Trust. Both Trust and Trustee were previously owned by Huifeng via its wholly owned subsidiary Shanghai Biological Focus center. For the three months ended March 31, 2018, the Company recognized losses of $121, as a result of the Company’s ownership position in the Hong Kong Joint Venture. There were no similar losses recognized in the prior year comparative period. In February 2016, AMVAC Netherlands BV made an investment in Biological Products for Agriculture (“Bi-PA”). Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of March 31, 2018, the Company’s ownership position in Bi-PA was 15%. The Company adopted the provisions of ASU 2016-01 on January 1, 2018 and has elected to measure its cost method investment without a readily determinable fair value at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no observable price changes in the quarter ended March 31, 2018. There were no observable price changes in the quarter ended March 31, 2018. There was no impairment on the investment as of March 31, 2018. The investment is not material and is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes – Income tax expense was $1,692 for the three months ended March 31, 2018, as compared to $1,380 for the three months ended March 31, 2017. The effective tax rate for the three months ended March 31, 2018 and 2017 was 26.0% and 28.5%, respectively. The effective tax rate is based on the projected income for the full year and is subject to ongoing review and adjustment by management. In December 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; and (ii) requiring companies to pay a one-time transition tax on certain unremitted earnings of foreign subsidiaries. The Tax Act also established new tax laws that affect 2018, including, but not limited to: (i) the reduction of the U.S. federal corporate tax rate discussed above; (ii) a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries; (iii) a new provision designed to tax global intangible low-taxed income (“GILTI”); (iv) the repeal of the domestic production activity deductions; (v) limitations on the deductibility of certain executive compensation; and (vi) limitations on the use of foreign tax credits to reduce the U.S. income tax liability. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. For the three months ended March 31, 2018, the Company did not obtain additional information affecting the provisional amount initially recorded for the transition tax for the three months ended December 31, 2017. As a result, the Company has not recorded an adjustment to the transition tax. Additional work is still necessary for a more detailed analysis of the Company's deferred tax assets and liabilities and its historical foreign earnings as well as potential correlative adjustments. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2018
Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region	Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended March 31, 2018 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 41,293 $ 41,317 Herbicides/soil fumigants/fungicides 32,185 32,185 Other, including plant growth regulators and distribution 17,840 17,840 91,318 91,342 Non-crop, including distribution 12,790 12,790 Total net sales: $ 104,108 $ 104,132 Net sales: US $ 69,815 $ 69,839 International 34,293 34,293 Total net sales: $ 104,108 $ 104,132 Timing of revenue recognition: Goods transferred at a point in time $ 103,705 $ 104,132 Goods and services transferred over time 403 — Total net sales: $ 104,108 $ 104,132
Summary of Receivables and Contract Liabilities from Contracts with Customers	The following table provides information about receivables and contract liabilities from contracts with customers: March 31, 2018 December 31, 2017 Total receivables, net $ 122,403 $ 109,605 Contract assets 3,000 — Deferred revenue 11,858 14,574
Accounting Standards Update 2014-09
Summary of Impact of Adoption to Condensed Consolidated Balance Sheet	The following table presents the effect of the adoption of ASU 2014-09 on our condensed consolidated balance sheet (unaudited) as of December 31, 2017, (in thousands): As of December 31, 2017 As previously reported Adjustment due to adoption of ASC 606 As adjusted Total assets $ 535,592 $ 3,000 $ 538,592 Deferred income tax liabilities, net 16,284 786 17,070 Retained earnings 238,953 2,214 241,167 In accordance with ASC 606, the disclosure of the impact of adoption to our condensed consolidated balance sheet was as follows: As of March 31, 2018 As reported Balances without adoption of ASC 606 Impact Assets: Contract assets $ 3,000 $ — $ 3,000 Current liabilities: Deferred revenue 11,858 11,834 24 Deferred income tax liabilities 786 — 786 Stockholders' equity: Retained earnings 245,056 242,842 2,214

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2018
Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment at March 31, 2018 and December 31, 2017 consists of the following: March 31, 2018 December 31, 2017 Land $ 2,458 $ 2,458 Buildings and improvements 16,732 16,678 Machinery and equipment 108,250 107,722 Office furniture, fixtures and equipment 5,179 4,713 Automotive equipment 1,010 735 Construction in progress 2,027 1,917 Total 135,656 134,223 Less accumulated depreciation (87,077 ) (84,902 ) Property, plant and equipment, net $ 48,579 $ 49,321

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories consist of the following: March 31, 2018 December 31, 2017 Finished products $ 125,498 $ 107,595 Raw materials 17,733 15,529 $ 143,231 $ 123,124

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Summary of Business Sales Segmentation	Selective enterprise information is as follows: Three Months Ended March 31 2018 2017 Net sales: Crop: Insecticides $ 41,293 $ 37,942 Herbicides/soil fumigants/fungicides 32,185 20,021 Other, including plant growth regulators and distribution 17,840 3,392 91,318 61,355 Non-crop, including distribution 12,790 9,318 Total net sales: $ 104,108 $ 70,673 Net sales: US $ 69,815 $ 52,244 International 34,293 18,429 Total net sales: $ 104,108 $ 70,673

Cash Dividend (Tables)

Cash Dividend (Tables)	3 Months Ended
	Mar. 31, 2018
Cash Dividends [Abstract]
Cash Dividend	The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid March 8, 2018 March 30, 2018 April 13, 2018 $ 0.020 $ 586 December 12, 2017 December 27, 2017 January 10, 2018 $ 0.015 $ 438

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended March 31, 2018 2017 Numerator: Net income attributable to AVD $ 4,655 $ 3,452 Denominator: Weighted averages shares outstanding-basic 29,282 28,947 Dilutive effect of stock options and grants 690 707 29,972 29,654

Indebtedness (Tables)

Indebtedness (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Summary of Revolving Line of Credit	The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at March 31, 2018 and December 31, 2017. The Company has no short term debt as of March 31, 2018 and December 31, 2017. The debt is summarized in the following table: Long-term indebtedness ($000's) March 31, 2018 December 31, 2017 Revolving line of credit $ 91,225 $ 78,425 Deferred loan fees (900 ) (939 ) Total indebtedness $ 90,325 $ 77,486

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months ended March 31, 2018 and 2017. Stock-Based Compensation for the Three months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) March 31, 2018 Restricted Stock $ 666 $ 7,956 2.0 Unrestricted Stock $ 96 $ 64 0.2 Performance Based Restricted Stock 547 3,562 2.4 Total $ 1,309 $ 11,582 March 31, 2017 Incentive Stock Options $ 84 $ 293 0.8 Restricted Stock 581 5,388 2.3 Unrestricted Stock 75 50 0.2 Performance Based Restricted Stock 300 2,385 2.5 Performance Based Options 40 128 0.8 Total $ 1,080 $ 8,244
Summary of Option Activity	Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Balance outstanding, December 31, 2017 472,783 $ 9.38 Options exercised (40,923 ) 11.49 Options forfeited — — Balance outstanding, March 31, 2018 431,860 $ 9.19
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2018, summarized by exercise price is as follows: Outstanding Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Incentive Stock Option Plan: $7.50 249,050 32 $ 7.5 $11.32—$14.49 182,810 77 $ 11.49 431,860 51 $ 9.19
Performance Based Stock Options
Summary of Option Activity	Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Balance outstanding, December 31, 2017 and March 31, 2018 81,666 $ 11.49
Performance Incentive Stock Option Plan
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2018 summarized by exercise price is as follows: Outstanding Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Performance Incentive Stock Option Plan: 81,666 81 $ 11.49
Common Stock Grants
Summary of Non-Vested Shares	Common stock grants — Three Months Ended March 31, 2018 Three Months Ended March 31, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 391,753 $ 15.63 324,756 $ 14.75 Granted 254,972 19.97 251,475 16.10 Vested (8,800 ) 12.07 (10,100 ) 12.95 Forfeited (5,265 ) 16.51 (6,544 ) 15.26 Nonvested shares at March 31 st 632,660 $ 17.42 559,587 $ 15.38
Performance Based Restricted Shares
Summary of Non-Vested Shares	Performance Based Shares — Three Months Ended March 31, 2018 Three Months Ended March 31, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 186,057 $ 14.93 119,022 $ 14.18 Granted 122,446 18.14 121,194 15.40 Vested (14,625 ) 11.09 — — Forfeited (1,765 ) 15.40 — — Nonvested shares at March 31 st 292,113 $ 16.46 240,216 $ 14.80

Accumulated Other Comprehensi35

Accumulated Other Comprehensive Income ("AOCI") (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Total Balance, December 31, 2016 $ (4,851 ) FX translation 344 Balance, December 31, 2017 (4,507 ) FX translation 672 Balance, March 31, 2018 $ (3,835 )

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)Segment	Mar. 31, 2017USD ($)
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Number of reportable segments | Segment	1
Remaining performance obligations	$ 44,079
Revenue recognized	12,740
Net sales	104,108	$ 70,673
Accounting Standards Update 2014-09 | Impact
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net sales	$ (24)

Revenue Recognition - Summary o

Revenue Recognition - Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region (Detail) - Accounting Standards Update 2014-09 $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Net sales
Net sales	$ 104,108
Insecticides
Net sales
Net sales	41,293
Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	32,185
Other, Including Plant Growth Regulators and Distribution
Net sales
Net sales	17,840
Crop
Net sales
Net sales	91,318
Non Crop Including Distribution
Net sales
Net sales	12,790
US
Net sales
Net sales	69,815
International
Net sales
Net sales	34,293
Goods Transferred At A Point In Time [Member]
Net sales
Net sales	103,705
Goods And Services Transferred Over Time [Member]
Net sales
Net sales	403
Balances without adoption of Topic 606
Net sales
Net sales	104,132
Balances without adoption of Topic 606 | Insecticides
Net sales
Net sales	41,317
Balances without adoption of Topic 606 | Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	32,185
Balances without adoption of Topic 606 | Other, Including Plant Growth Regulators and Distribution
Net sales
Net sales	17,840
Balances without adoption of Topic 606 | Crop
Net sales
Net sales	91,342
Balances without adoption of Topic 606 | Non Crop Including Distribution
Net sales
Net sales	12,790
Balances without adoption of Topic 606 | US
Net sales
Net sales	69,839
Balances without adoption of Topic 606 | International
Net sales
Net sales	34,293
Balances without adoption of Topic 606 | Goods Transferred At A Point In Time [Member]
Net sales
Net sales	$ 104,132

Revenue Recognition - Summary38

Revenue Recognition - Summary of Receivables and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Contract With Customer Liability [Abstract]
Total receivables, net	$ 122,403	$ 109,605
Contract assets	3,000
Deferred revenue	$ 11,858	$ 14,574

Revenue Recognition - Summary39

Revenue Recognition - Summary of Adoption of ASU 2014-09 on Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets	$ 566,793	$ 535,592
Deferred income tax liabilities, net	17,250	16,284
Retained earnings	245,056	238,953
Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Retained earnings	245,056
Adjustment Due to Adoption of Topic 606 | Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets		3,000
Deferred income tax liabilities, net		786
Retained earnings	2,214	2,214
Balances without adoption of Topic 606 | Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets		538,592
Deferred income tax liabilities, net		17,070
Retained earnings	$ 242,842	$ 241,167

Revenue Recognition - Summary40

Revenue Recognition - Summary of Impact of Adoption to Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Assets:
Contract assets	$ 3,000
Current liabilities:
Deferred revenue	11,858	$ 14,574
Stockholders' equity:
Retained earnings	245,056	238,953
Accounting Standards Update 2014-09
Assets:
Contract assets	3,000
Current liabilities:
Deferred revenue	11,858
Deferred income tax liabilities	786
Stockholders' equity:
Retained earnings	245,056
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606
Current liabilities:
Deferred revenue	11,834
Stockholders' equity:
Retained earnings	242,842	241,167
Accounting Standards Update 2014-09 | Impact
Assets:
Contract assets	3,000
Current liabilities:
Deferred revenue	24
Deferred income tax liabilities	786
Stockholders' equity:
Retained earnings	$ 2,214	$ 2,214

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total gross value	$ 135,656	$ 134,223
Less accumulated depreciation	(87,077)	(84,902)
Property, plant and equipment, net	48,579	49,321
Land
Property, Plant and Equipment [Line Items]
Total gross value	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total gross value	16,732	16,678
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total gross value	108,250	107,722
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total gross value	5,179	4,713
Automotive equipment
Property, Plant and Equipment [Line Items]
Total gross value	1,010	735
Construction in progress
Property, Plant and Equipment [Line Items]
Total gross value	$ 2,027	$ 1,917

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Depreciation expense related to property, plant and equipment	$ 2,303	$ 1,950
Elimination of Assets and Accumulated depreciation	$ 128	$ 1,175

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished products	$ 125,498	$ 107,595
Raw materials	17,733	15,529
Total Inventories	$ 143,231	$ 123,124

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018Segment
Segment Reporting [Abstract]
Number of reportable business segments	1

Summary of Business Sales by Pr

Summary of Business Sales by Product and Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net sales
Net sales	$ 104,108	$ 70,673
Insecticides
Net sales
Net sales	41,293	37,942
Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	32,185	20,021
Other, Including Plant Growth Regulators and Distribution
Net sales
Net sales	17,840	3,392
Crop
Net sales
Net sales	91,318	61,355
Non Crop Including Distribution
Net sales
Net sales	12,790	9,318
US
Net sales
Net sales	69,815	52,244
International
Net sales
Net sales	$ 34,293	$ 18,429

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Cash dividend declaration date	Mar. 8, 2018	Dec. 12, 2017
Cash dividend record date	Mar. 30, 2018	Dec. 27, 2017
Cash dividend distributed date	Apr. 13, 2018	Jan. 10, 2018
Cash dividend per share	$ 0.020	$ 0.015
Cash dividend paid	$ 586	$ 438

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Numerator:
Net income attributable to AVD	$ 4,655	$ 3,452
Denominator:
Weighted average shares outstanding—basic	29,282	28,947
Dilutive effect of stock options and grants	690	707
Weighted averages shares outstanding-assuming dilution	29,972	29,654

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Stock options excluded from computation of diluted earning per share	0	0

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2017	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Debt Instrument [Line Items]
Short term debt		$ 0	$ 0
Senior secured credit facility, maturity date	Jun. 30, 2022
Revolving Credit Facility
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement				$ 119,994,000
Maximum
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	$ 250,000,000
Consolidated funded debt ratio	325.00%
Maximum | Revolving Credit Facility
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement		$ 124,936,000
Maximum | Term Loan
Debt Instrument [Line Items]
Accordion feature	$ 100,000,000
Minimum
Debt Instrument [Line Items]
Consolidated fixed charge covenant ratio	125.00%

Summary of Revolving Line of Cr

Summary of Revolving Line of Credit (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Revolving line of credit	$ 91,225	$ 78,425
Deferred loan fees	(900)	(939)
Total indebtedness	$ 90,325	$ 77,486

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 1,309	$ 1,080
Unamortized Stock-Based Compensation	11,582	8,244
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation		$ 84
Remaining Weighted Average Period (years)		9 months 18 days
Unamortized Stock-Based Compensation		$ 293
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 666	$ 581
Remaining Weighted Average Period (years)	2 years	2 years 6 months
Unamortized Stock-Based Compensation	$ 7,956	$ 5,388
Unrestricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 96	$ 75
Remaining Weighted Average Period (years)	2 months 12 days	2 months 12 days
Unamortized Stock-Based Compensation	$ 64	$ 50
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 547	$ 300
Remaining Weighted Average Period (years)	2 years 4 months 24 days	2 years 6 months
Unamortized Stock-Based Compensation	$ 3,562	$ 2,385
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation		$ 40
Remaining Weighted Average Period (years)		9 months 18 days
Unamortized Stock-Based Compensation		$ 128

Summary of Option Activity (Det

Summary of Option Activity (Detail) - Incentive Stock Options	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance | shares	472,783
Incentive Stock Option Plans, Option exercised | shares	(40,923)
Incentive Stock Option Plans, Ending balance | shares	431,860
Weighted Average Price Per Share, Beginning balance | $ / shares	$ 9.38
Weighted Average Price Per Share, Option exercised | $ / shares	11.49
Weighted Average Price Per Share, Ending balance | $ / shares	$ 9.19

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
All outstanding awards, Intrinsic value, Vested	$ 711
Number of Shares, Granted	0	0
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
All outstanding awards, Intrinsic value, Vested	$ 4,757
Remaining Weighted Average Period (years)		9 months 18 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years of service before cliff vesting	3 years	3 years
Weighted Average Grant-Date Fair Value, Granted	$ 19.97	$ 16.10
Unamortized Stock-Based Compensation	$ 7,956	$ 5,388
Remaining Weighted Average Period (years)	2 years	2 years 6 months
Number of Shares, Granted	254,972	251,475
Restricted Stock | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued by equity investee	254,972	251,475
Weighted Average Grant-Date Fair Value, Granted	$ 19.97	$ 16.10
Unvested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized Stock-Based Compensation	$ 7,956	$ 5,388
Remaining Weighted Average Period (years)	2 years	1 year 4 months 24 days
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted	$ 18.14	$ 15.40
Unamortized Stock-Based Compensation	$ 3,562	$ 2,385
Remaining Weighted Average Period (years)	2 years 4 months 24 days	2 years 6 months
Number of Shares, Granted	122,446	121,194
Targeted performance percentage		200.00%
Performance Based Restricted Shares | Vested on March 9, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date	Mar. 9, 2021	Feb. 8, 2020
Performance Based Restricted Shares | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2018 through December 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance	80.00%
Earnings before income tax goal weight, percentage	50.00%
Net sales goal weight, percentage	30.00%
Performance Based Restricted Shares | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2018 through December 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income tax goal weight, percentage	20.00%
Performance Based Restricted Shares | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2017 through December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance		80.00%
Earnings before income tax goal weight, percentage		50.00%
Net sales goal weight, percentage		30.00%
Performance Based Restricted Shares | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2017 through December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income tax goal weight, percentage		20.00%
Performance Based Restricted Shares | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2018 and Ending December 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted	$ 19.95
Performance Based Restricted Shares | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2018 and Ending December 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted	$ 16.49
Unvested Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized Stock-Based Compensation	$ 3,562	$ 2,385
Remaining Weighted Average Period (years)	2 years 4 months 24 days	1 year 3 months 18 days

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - Incentive Stock Options - $ / shares	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	431,860
Outstanding Weighted Average, Remaining Life (Months)	51 months
Outstanding Weighted Average, Exercise Price	$ 9.19	$ 9.38
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	249,050
Outstanding Weighted Average, Remaining Life (Months)	32 months
Outstanding Weighted Average, Exercise Price	$ 7.5
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.49
Outstanding Weighted Average, Shares	182,810
Outstanding Weighted Average, Remaining Life (Months)	77 months
Outstanding Weighted Average, Exercise Price	$ 11.49

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - Common Stock Grants - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	391,753	324,756
Number of Shares, Granted	254,972	251,475
Number of Shares, Vested	(8,800)	(10,100)
Number of Shares, Forfeited	(5,265)	(6,544)
Number of Shares, Ending Balance	632,660	559,587
Weighted Average Grant-Date Fair Value, Beginning balance	$ 15.63	$ 14.75
Weighted Average Grant-Date Fair Value, Granted	19.97	16.10
Weighted Average Grant-Date Fair Value, Vested	12.07	12.95
Weighted Average Grant-Date Fair Value, Forfeited	16.51	15.26
Weighted Average Grant-Date Fair Value, Ending balance	$ 17.42	$ 15.38

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - Performance Based Restricted Shares - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	186,057	119,022
Number of Shares, Granted	122,446	121,194
Number of Shares, Vested	(14,625)
Number of Shares, Forfeited	(1,765)
Number of Shares, Ending Balance	292,113	240,216
Weighted Average Grant-Date Fair Value, Beginning balance	$ 14.93	$ 14.18
Weighted Average Grant-Date Fair Value, Granted	18.14	15.40
Weighted Average Grant-Date Fair Value, Vested	11.09
Weighted Average Grant-Date Fair Value, Forfeited	15.40
Weighted Average Grant-Date Fair Value, Ending balance	$ 16.46	$ 14.80

Summary of Performance option a

Summary of Performance option activity (Detail) - Performance Based Stock Options - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans	81,666	81,666
Weighted Average Price Per Share	$ 11.49	$ 11.49

Performance Options Summarized

Performance Options Summarized by Exercise Price (Detail) - Performance Incentive Stock Option Plan	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares | shares	81,666
Outstanding Weighted Average, Remaining Life (Months)	81 months
Outstanding Weighted Average, Exercise Price | $ / shares	$ 11.49

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Detail) $ in Thousands	May 31, 2012USD ($)CasePersonPlaintiff
U.S. State District Court Abad Castillo And Marquinez
Loss Contingencies [Line Items]
Number of Lawsuits Filed	2
Number of claimants | Person	2,700
U.S. State District Court Abad Castillo | Hendler Law Firm
Loss Contingencies [Line Items]
Number of plaintiffs required to be dismissed | Plaintiff	22
Number of plaintiffs dismissed	14
Superior Court Abad Castillo And Marquinez
Loss Contingencies [Line Items]
Number of Lawsuits appealed	57
United States Lawsuits
Loss Contingencies [Line Items]
Legal costs and fees | $	$ 2,350

Recently Issued Accounting Gu60

Recently Issued Accounting Guidance - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Jan. 01, 2018
Adopted ASU 2016-16
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impact of adjustment to retain earnings		$ (180)
Adopted ASU 2015-16
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Adjustment to goodwill	$ 799

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 305,314
Foreign currency translation adjustment	672	$ 757
Balance	314,158		$ 305,314
Accumulated Foreign Currency Adjustment Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(4,507)	$ (4,851)	(4,851)
Foreign currency translation adjustment	672		344
Balance	$ (3,835)		$ (4,507)

Equity Method Investments - Add

Equity Method Investments - Additional Information (Detail) - USD ($)	Jul. 07, 2017	Jun. 27, 2017	Mar. 31, 2018	Mar. 31, 2017	Jan. 31, 2018	Dec. 31, 2017
Equity Method Investments [Line Items]
Gain (loss) from equity method investment			$ (217,000)	$ (42,000)
Investment		$ 950,000
Profeng Australia, Pty Ltd
Equity Method Investments [Line Items]
Joint venture, consideration	$ 1,900,000
Bi-PA
Equity Method Investments [Line Items]
Equity investment ownership position			15.00%
Cost-method Investments, Other than Temporary Impairment			$ 0
TyraTech Inc.
Equity Method Investments [Line Items]
Equity investment ownership position					34.38%	15.11%
Gain (loss) from equity method investment			$ (96,000)	(42,000)
Hong Kong JV
Equity Method Investments [Line Items]
Equity investment ownership position			50.00%
Gain (loss) from equity method investment			$ 121,000	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,692	$ 1,380
Effective tax rate	26.00%	28.50%
Federal Income Tax Rate	21.00%		35.00%